Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2021 | 409 | 1.430 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2021 | 42 | 1.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2021 | 144 | 1.070 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 356 | 1.050 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 540 | 0.950 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2021 | 105 | 0.800 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2019 | 4 | 0.620 |
Why?
|
| Pancreatitis | 1 | 2019 | 36 | 0.600 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2021 | 14 | 0.510 |
Why?
|
| Interleukin-10 | 3 | 2021 | 72 | 0.500 |
Why?
|
| Polyethylene Glycols | 3 | 2021 | 101 | 0.480 |
Why?
|
| Neoplasms | 6 | 2021 | 808 | 0.470 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2019 | 39 | 0.460 |
Why?
|
| Middle Aged | 16 | 2021 | 7138 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 4 | 2018 | 329 | 0.420 |
Why?
|
| Pyrimidines | 4 | 2021 | 125 | 0.410 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 29 | 0.360 |
Why?
|
| Female | 17 | 2021 | 15155 | 0.320 |
Why?
|
| Aged | 12 | 2021 | 5400 | 0.290 |
Why?
|
| Humans | 22 | 2022 | 28095 | 0.290 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 277 | 0.290 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 679 | 0.260 |
Why?
|
| Pyrroles | 3 | 2021 | 36 | 0.260 |
Why?
|
| B7-H1 Antigen | 3 | 2021 | 38 | 0.250 |
Why?
|
| Male | 14 | 2021 | 13490 | 0.240 |
Why?
|
| Leucovorin | 2 | 2020 | 19 | 0.220 |
Why?
|
| Fluorouracil | 2 | 2020 | 58 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 194 | 0.190 |
Why?
|
| Organoplatinum Compounds | 2 | 2020 | 24 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 38 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 82 | 0.180 |
Why?
|
| Indazoles | 1 | 2021 | 18 | 0.180 |
Why?
|
| Oxazepines | 1 | 2020 | 4 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 15 | 0.180 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2020 | 1 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 607 | 0.170 |
Why?
|
| Platinum | 1 | 2020 | 18 | 0.170 |
Why?
|
| Fatal Outcome | 1 | 2020 | 67 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2021 | 73 | 0.170 |
Why?
|
| Imidazoles | 1 | 2020 | 63 | 0.170 |
Why?
|
| Adult | 10 | 2021 | 7740 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 77 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 162 | 0.170 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2020 | 55 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 101 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2019 | 4 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2019 | 9 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2019 | 27 | 0.160 |
Why?
|
| Liposomes | 1 | 2020 | 145 | 0.160 |
Why?
|
| Time Factors | 2 | 2020 | 1591 | 0.160 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2018 | 2 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 270 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 138 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2018 | 9 | 0.150 |
Why?
|
| Acute Disease | 1 | 2019 | 155 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2018 | 62 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 112 | 0.150 |
Why?
|
| Platinum Compounds | 1 | 2017 | 14 | 0.140 |
Why?
|
| Recurrence | 1 | 2019 | 322 | 0.140 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 13 | 0.140 |
Why?
|
| Urothelium | 1 | 2017 | 35 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 474 | 0.140 |
Why?
|
| Prognosis | 4 | 2022 | 802 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 179 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2018 | 110 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 163 | 0.140 |
Why?
|
| Carcinoma | 1 | 2017 | 74 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 282 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 473 | 0.130 |
Why?
|
| Mutation | 1 | 2020 | 845 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2020 | 287 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 301 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 214 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 465 | 0.120 |
Why?
|
| Taxoids | 2 | 2013 | 37 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 2021 | 0.110 |
Why?
|
| Thorax | 1 | 2013 | 29 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2013 | 41 | 0.110 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2013 | 3 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 478 | 0.100 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2013 | 14 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 669 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1013 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 149 | 0.090 |
Why?
|
| Denosumab | 1 | 2011 | 2 | 0.090 |
Why?
|
| Androstenols | 1 | 2011 | 2 | 0.090 |
Why?
|
| Androstenes | 1 | 2011 | 3 | 0.090 |
Why?
|
| Tissue Extracts | 1 | 2011 | 7 | 0.090 |
Why?
|
| RANK Ligand | 1 | 2011 | 19 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2011 | 15 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2021 | 2378 | 0.080 |
Why?
|
| Young Adult | 3 | 2021 | 2733 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 2 | 2019 | 31 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2020 | 417 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2019 | 137 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 589 | 0.070 |
Why?
|
| Carboplatin | 2 | 2019 | 111 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2019 | 190 | 0.060 |
Why?
|
| United States | 2 | 2019 | 2146 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 31 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 1319 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 18 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 42 | 0.050 |
Why?
|
| Pyrazines | 1 | 2021 | 24 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 63 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2021 | 66 | 0.040 |
Why?
|
| Topotecan | 1 | 2020 | 12 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 7 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 224 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 288 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 19 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2018 | 21 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 25 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 179 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 430 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 722 | 0.040 |
Why?
|
| Species Specificity | 1 | 2018 | 192 | 0.040 |
Why?
|
| Leptin | 1 | 2018 | 67 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1248 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2018 | 76 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2020 | 887 | 0.040 |
Why?
|
| Platelet Count | 1 | 2018 | 111 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 20 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 206 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2018 | 118 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2017 | 69 | 0.040 |
Why?
|
| Body Weight | 1 | 2018 | 250 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 98 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 237 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 160 | 0.030 |
Why?
|
| Diet | 1 | 2018 | 232 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 487 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 806 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2546 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 1576 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 113 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 3122 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2013 | 65 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 300 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 190 | 0.020 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 65 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 1435 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 10418 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 331 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 269 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 177 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 373 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 404 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 1461 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 4652 | 0.010 |
Why?
|